Eli Lilly and Company (NYSE:LLY) Shares Gap Up – Should You Buy?

Shares of Eli Lilly and Company (NYSE:LLY) gapped up before the market opened on Monday . The stock had previously closed at $1,009.52, but opened at $1,047.02. Eli Lilly and Company shares last traded at $1,047.7380, with a volume of 651,029 shares.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rival trial miss reinforces Lilly’s clinical edge and likely market share gains — investors are re‑pricing demand in Lilly’s favor after Novo Nordisk said its next‑generation obesity drug failed to demonstrate non‑inferiority to Lilly’s tirzepatide in an 84‑week study; Novo shares plunged and Lilly shares gained on the news. Novo Nordisk’s obesity drug falls short against Eli Lilly’s in Copenhagen trial
• Positive Sentiment: FDA approval and launch of a multi‑dose Zepbound KwikPen reduces patient friction and could improve retention/adherence — Lilly will sell the month‑long pen at the same self‑pay price, widening choice and potentially supporting longer treatment duration and sales stability. Zepbound now available in multi-dose KwikPen (PR Newswire)
• Positive Sentiment: Institutional/hedge‑fund buying lifted flows into ETFs concentrated in mega‑caps including Lilly — positioning by large investors can amplify upward momentum in the stock. Hedge Funds’ Mag 7, Eli Lilly Buying Spree Sparks Massive ETF Accumulation
• Neutral Sentiment: Analysts/upgrades continue to support the narrative — recent price‑target raises and positive outlook notes (e.g., Erste Group, other street coverage) back the bullish consensus but are reiterations rather than new catalysts. Erste Group Bank Has Positive Outlook of LLY FY2026 Earnings
• Negative Sentiment: Large historical insider selling and some institutional rebalancing are noted in data services — while not new, continued disclosure of heavy insider sales or big fund position shifts could be an ongoing watch‑item for risk‑aware investors. Eli Lilly rises as rival obesity-drug trial data strengthen tirzepatide’s edge (Quiver Quant)

Wall Street Analysts Forecast Growth

LLY has been the topic of several research reports. The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Truist Financial set a $1,281.00 price objective on Eli Lilly and Company in a research note on Thursday, February 5th. TD Cowen lifted their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,228.54.

Eli Lilly and Company Trading Up 4.0%

The firm has a market capitalization of $990.08 billion, a P/E ratio of 45.78, a P/E/G ratio of 1.17 and a beta of 0.39. The company’s fifty day moving average is $1,054.83 and its 200-day moving average is $917.84. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the previous year, the firm earned $5.32 EPS. The firm’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 30.15%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Kera Capital Partners Inc. grew its holdings in shares of Eli Lilly and Company by 35.4% in the 4th quarter. Kera Capital Partners Inc. now owns 761 shares of the company’s stock valued at $789,000 after acquiring an additional 199 shares in the last quarter. Walser Wealth Management Company A Ltd Liability Co bought a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $1,332,000. Copos Capital S.a r.l. acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $74,000. MV Capital Management Inc. acquired a new position in Eli Lilly and Company during the 4th quarter worth about $2,652,000. Finally, Vinland Capital Management Gestora de Recursos LTDA. bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $185,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.